04:16 AM EDT, 09/10/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Wednesday it priced a public offering of 17.5 million shares at $10 each, aiming to raise $175 million in gross proceeds.

Underwriters have a 30-day overallotment option to purchase up to 2.63 million additional shares.

The company intends to use the proceeds to prepare for the commercialization of Avexitide, fund research and development, and support general corporate purposes.

The offering is expected to close by Thursday.